US drug body approves Merus' therapy for lung, pancreatic cancer patients

Q: How long will it take to read this news story?

The story "US drug body approves Merus&#039; therapy for lung, pancreatic cancer patients" has 372 words across 15 sentences, which will take approximately 2 - 4 minutes for the average person to read.

Q: Which news outlet covered this story?

The story "US drug body approves Merus&#039; therapy for lung, pancreatic cancer patients" was covered 2 weeks ago by Business Standard, a news publisher based in India.

Q: How trustworthy is 'Business Standard' news outlet?

Business Standard is a fully independent (privately-owned) news outlet established in 1975 that covers mostly business and finance news. The outlet is headquartered in India and publishes an average of 210 news stories per day. It's most recent story was published 2 hours ago.

Q: What do people currently think of this news story?

The sentiment for this story is currently Neutral, indicating that people are not responding positively or negatively to this news.

Q: How do I report this news for inaccuracy?

You can report an inaccurate news publication to us via our contact page. Please also include the news #ID number and the URL to this story.<ul><li>News ID: #24129858</li><li>URL: https://beamstart.com/news/us-drug-body-approves-merus-17333700778215</li></ul>

Business Standard Logo Business Standard 2w ago

US drug body approves Merus' therapy for lung, pancreatic cancer patients - Business Standard

Quick Summary:

The recommended dose of the therapy is 750 milligrams, as an intravenous infusion every 2 weeks, the health regulator said.

The therapy works by blocking the interaction between a protein called HER3 and the NRG1 gene, which in turns inhibits the growth of tumor cells.

On Monday, the company announced an agreement with Partner Therapeutics, under which the private biotech would assume full rights to U.S.commercialization of Bizengri. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.